Case Studies: Mecwins-Quidel

Co-developing an ultra-sensistive

diagnostic technology in the

Point-of-Care space

Introduction

It is well known that conventional technologies are not able to detect molecules in low concentrations and ultrasensitivity can be a differentiating factor for high-throughput platforms particularly in IVD markets, where an earlier and more precise detection of key biomarkers, particularly in the areas of oncology, cardiology and infectious diseases, is a driving market force.

Mecwins, a Spanish company founded in 2008 that develops nanotechnological solutions for unmet needs in medical diagnosis based on ultrasensitive and multiplexing technology for biomarker detection, was looking for co-development and commercialization partners for their AVAC technology, a robust and versatile platform with a demonstrated high sensitivity performance in a range of biomakers related to different diseases, including cardiometabolic, infectious, neurodegenerative and oncologic.

To achieve this, Mecwins partnered with trifermed to run a competitive partnering process with the objective of identifying strategic partners that could take care of certain key activities.

Through trifermed’s structured methodology and strategic partnerships knowledge, Mecwins, secured a licensing and co-development agreement with Quidel (now QuidelOrtho) leveraging Mecwins’ ultrasensitive AVAC platform and Quidel’s extensive expertise in POC assay and cartridge development.

Background

Mecwins sought partners that could:

-              Co-develop a final IVD product in a desired market indication (identification, development and validation of biomarkers of interest)

-              Manufacture the final product to be commercialized

-              Get the product through regulatory approval and commercialization

Trifermed was engaged to identify and facilitate these strategic partnerships, leveraging its extensive network, expertise in business development, and deep understanding of market dynamics in the medtech industry.​

Services Provided

  • Business Model Design, Strategy Discussion and Project Scope Definition​ –Partner Profile Definition

  • Partner Identification & Evaluation​: Contacting diagnostic companies at a global level, prioritising USA, EU, Japan and China.

  • Deal Structuring & Negotiation Support​

Outcomes & Future Development

As a result of trifermed’s work, Mecwins secured a strategic co-development and licensing partnership at a global level with a knowleadgeable company in the IVD sector, Quidel, aiming to facilitate the development of new tests, and incorporate new biomarkers and indications.

These agreement mainly enabled:​

  • Product development continuation

  • Market validation: reinforcing AVAC’s value proposition as an offering that could allow other companies to better position themsevels in the current market.